Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PHASE 1-2 STUDY EVALUATING HIGH DOSE ADXS11-001 (1 x 10^10 CFU) TREATMENT IN WOMEN WITH HPV+ CARCINOMA OF THE CERVIX

Trial Profile

PHASE 1-2 STUDY EVALUATING HIGH DOSE ADXS11-001 (1 x 10^10 CFU) TREATMENT IN WOMEN WITH HPV+ CARCINOMA OF THE CERVIX

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 07 Mar 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Axalimogene filolisbac (Primary)
  • Indications Adenocarcinoma; Adenosquamous carcinoma; Cervical cancer; Squamous cell cancer
  • Focus Adverse reactions
  • Sponsors Advaxis
  • Most Recent Events

    • 04 Mar 2019 Status changed from active, no longer recruiting to completed.
    • 15 May 2017 According to an Advaxis media release, Sharad Ghamande from Georgia Cancer Center at Augusta University is the principal investigator of this trial.
    • 27 Mar 2017 According to an Advaxis media release, one patient from this trial was featured in the Augusta Chronicle.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top